First inappropriate implantable cardioverter defibrillator therapy is often due to inaccurate device programming: Analysis of the French OPERA registry

Europace

Volumn 14, Issue 10, 2012, Pages 1465-1474

  Leenhardt, Antoine ^a   Defaye, Pascal ^b   Mouton, Elisabeth ^c   Delay, Marc ^d   Delarche, Nicolas ^e   Dupuis, Jean Marc ^f   Bizeau, Olivier ^g   Mabo, Philippe ^h   Cheggour, Saida ⁱ   Babuty, Dominique ^j  

^a BICHAT HOSPITAL   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c Guidant/Boston Scientific   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e CENTRE HOSPITALIER DE PAU   (France)

^f ANGERS UNIVERSITY HOSPITAL   (France)

^g Centre Hospitalier Regional   (France)

^h RENNES UNIVERSITY HOSPITAL   (France)

ⁱ CENTRE HOSPITALIER D AVIGNON   (France)

^j UNIVERSITY HOSPITAL OF TOURS   (France)

more..

Author keywords

Atrial fibrillation; Implantable cardioverter defibrillator; Inappropriate therapy; Supraventricular tachyarrhythmia; Ventricular tachyarrhythmia

Indexed keywords

ADULT; ALGORITHM; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; DEFIBRILLATOR; FEMALE; FRANCE; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGISTER; TREATMENT FAILURE;

AGED; ALGORITHMS; CARDIAC RESYNCHRONIZATION THERAPY; DEFIBRILLATORS, IMPLANTABLE; FEMALE; FRANCE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSTHESIS FAILURE; REGISTRIES; TACHYCARDIA, SUPRAVENTRICULAR; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME;

EID: 84866904168     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eus144     Document Type: Article

References (32)

1. Gregoratos G, Abrams J, Epstein AE, Freedman RA, Hayes DL, Hlatky MA, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines/North American Society for Pacing and Electrophysiology Committee to update the 1998 Pacemaker Guidelines. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to update the 1998 Pacemaker Guidelines). Circulation 2002;106: 2145-61.
2. Goldberger Z, Lampert R. Implantable cardioverter-defibrillators: expanding indications and technologies. JAMA 2006;295:809-18.
3. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-40.
4. Nanthakumar K, Dorian P, Paquette M, Greene M, Edwards J, Heng D, et al. Is inappropriate implantable defibrillator shock therapy predictable? J Interv Card Electrophysiol 2003;8:215-20.
5. Boriani G, Occhetta E, Pistis G, Menozzi C, Jorfida M, Sermasi S, et al. Combined use of morphology discrimination, sudden onset, and stability as discriminating algorithms in single chamber cardioverter defibrillators. Pacing Clin Electrophysiol 2002;25:1357-66.
6. Avitall B, Port S, Gal R, McKinnie J, Tchou P, Jazayeri M, et al. Automatic implantable cardioverter/defibrillator discharges and acute myocardial injury. Circulation 1990;81:1482-87.
7. Finkelmeier B, Kenwood N, Summers C. Psychological ramifications of surviving sudden cardiac death. Crit Care Q 1984;1:71-9.
8. Schron EB, Exner DV, Yao Q, Jenkins LS, Steinberg JS, Cook JR, et al. Quality of Life in the Antiarrhythmics Versus Implantable Defibrillators Trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 2002;105:589-94.
9. Sweeney MO, Wathen MS, Volosin K, Abdalla I, DeGroot PJ, Otterness MF, et al. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT Reduces Shock ThErapies (PainFREE Rx II) trial. Circulation 2005;111:2898-905.
10. Daubert JP, Zareba W, Cannom DS, McNitt S, Rosero SZ, Wang P, et al., MADIT II Investigators. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 2008;51:1357-65.
11. Israel CW. How to avoid inappropriate therapy. Curr Opin Cardiol 2008;23:65-71.
12. Glikson M, Lipchenca I, Viskin S, Ballman KV, Trusty JM, Gurevitz OT, et al. Longterm outcome of patients who received implantable cardioverter defibrillators for stable ventricular tachycardia. J Cardiovasc Electrophysiol 2004;15:658-64.
13. Germano JJ, Reynolds M, Essebag V, Josephson ME. Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic? Am J Cardiol 2006;97:1255-61.
14. Sorbera C. Risk factors for appropriate cardioverter-defibrillator shocks, inappropriate cardioverter-defibrillator shocks, and time to mortality in 549 patients with heart failure. Am J Cardiol 2010;105:1336-8.
15. Dorian P, Philippon F, Thibault B, Kimber S, Sterns L, Greene M, et al., ASTRID Investigators. Randomized controlled study of detection enhancements versus rate-only detection to prevent inappropriate therapy in a dual-chamber implantable cardioverter-defibrillator. Heart Rhythm 2004;1:540-7.
16. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al., Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933-40.
17. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al., Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
18. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial investigators. N Engl J Med 1999;341:1882-90.
19. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50.
20. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al., Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-7.
21. Da Rosa MR, Sapp JL, Howlett JG, Falkenham A, Le'garé JF. Implantable cardioverter-defibrillator implantation as a bridge to cardiac transplantation. J Heart Lung Transplant 2007;26:1336-9.
22. Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007;298:405-12.
23. Gold MR, Shorofsky SR, Thompson JA, Kim J, Schwartz M, Bocek J, et al. Advanced rhythm discrimination for implantable cardioverter defibrillators using electrogram vector timing and correlation. J Cardiovasc Electrophysiol 2002;13:1092-7.
24. Corbisiero R, Lee MA, Nabert DR, Coman JA, Breiter DJ, Schwartz M, et al. Performance of a new single-chamber ICD algorithm: discrimination of supraventricular and ventricular tachycardia based on vector timing and correlation. Europace 2006;8:1057-61.
25. Swerdlow CD, Friedman PA. Advanced ICD troubleshooting: part I. Pacing Clin Electrophysiol 2005;28:1322-46.
26. Aliot E, Nitzsché R, Ripart A. Arrhythmia detection by dual-chamber implantable cardioverter defibrillators. A review of current algorithms. Europace 2004;6: 273-86.
27. Saxon LA, Greenfield RA, Crandall BG, Nydegger CC, Orlov M, Van Genderen R. Results of the multicenter RENEWAL 3 AVT clinical study of cardiac resynchronization defibrillator therapy in patients with paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 2006;17:520-5.
28. Santini M, Russo M, Botto G, Lunati M, Proclemer A, Schmidt B, et al. Clinical and arrhythmic outcomes after implantation of a defibrillator for primary prevention of sudden death in patients with post-myocardial infarction cardiomyopathy: the Survey to Evaluate Arrhythmia Rate in High-risk MI patients (SEARCH-MI). Europace 2009;11:476-82.
29. Kreuz J, Balta O, Liliegren N, Mellert F, Esmailzadeh B, Nickenig G, et al. Incidence and characteristics of appropriate and inappropriate therapies in recipients of ICD implanted for primary prevention of sudden cardiac death. Pacing Clin Electrophysiol 2007;30:S125-7.
30. Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverteur defibrillators: the OPTIC Study: a randomized trial. JAMA 2006;295:165-71.
31. Satomi K, Kurita T, Takatsuki S, Yokoyama Y, Chinushi M, Tsuboi N, et al. Amiodarone therapy in patients implanted with cardioverter-defibrillator for lifethreatening ventricular arrhythmias. Circulation 2006;70:977-84.
32. Kleemann T, Becker T, Doenges K, Vater M, Senges J, Schneider S, et al. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of .10 years. Circulation 2007;115: 2474-80.